Stock 2162 KEYMED BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Delayed Hong Kong S.E.
Other stock markets
 01:50:02 2024-04-25 am EDT 		5-day change 1st Jan Change
34.25 HKD +1.78% Intraday chart for Keymed Biosciences Inc. +15.51% -30.24%
Apr. 12 Keymed Biosciences Advances Solid Tumors Drug With First Patient Study MT
Mar. 27 KeyMed Biosciences’ Attributable Loss Widens in 2023 MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
KEYMED BIOSCIENCES INC. Stock Keymed Biosciences Inc.
-30.24% 1.19B -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 104B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.42B
B+
ARGENX SE Stock argenx SE
+1.86% 22.2B
B
BIONTECH SE Stock BioNTech SE
-16.53% 21.23B
B+
GENMAB A/S Stock Genmab A/S
-8.49% 18.33B
A-
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.35B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 15.06B
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 13.98B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 11.66B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 2162 Stock
  4. Ratings Keymed Biosciences Inc.